Targeting the EGF receptor in breast cancer treatment.

Abstract:

:Immunotoxins are a relatively new class of cytotoxic agents consisting of a catalytic toxin linked to an appropriate targeting ligand. The ligand directs the toxin to the surface of a tumor cell, whereupon the toxin enters the cell and catalytically inactivates the ribosome, thus disrupting protein synthesis and effecting cell death. Monoclonal antibodies (or their fragments) have been most commonly used to carry chemically conjugated toxins to proteins or antigens overexposed on the tumor cell surface, but specific ligands for tumor cell surface receptors could also provide effective targeting. The receptor for epidermal growth factor (EGFR) is overexpressed primarily in poor prognosis breast cancers that do not respond well to traditional therapies. Because EGFR is frequently overexpressed in breast cancer tissue and is associated with a poor prognosis, it is an attractive target for antitumor therapy. DAB389EGF is an EGFR specific fusion toxin produced with recombinant DNA techniques consisting of sequences for the enzymatically active and membrane translocation domains of diphtheria toxin plus sequences for human epidermal growth factor. DAB389EGF is a potent, EGFR specific, cytotoxic agent which rapidly inhibits protein synthesis by a mechanism of action similar to that of diphtheria itself. Preclinical studies in the laboratory and in animals now suggest the feasibility of investigating such an agent in the targeted therapy of patients with human breast cancer.

authors

LeMaistre CF,Meneghetti C,Howes L,Osborne CK

doi

10.1007/BF00666210

subject

Has Abstract

pub_date

1994-01-01 00:00:00

pages

97-103

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

32

pub_type

杂志文章,评审
  • Tamoxifen-induced increases in cytoplasmic free Ca2+ levels in human breast cancer cells.

    abstract::Tamoxifen has been shown to increase cytoplasmic free Ca2+ levels [Ca2+]i in renal tubular cells and bladder cancer cells, and to after Ca2+ signaling in MCF-7 breast cancer cells. The present study examined the effect of tamoxifen on [Ca2+], in ZR-75-1 human breast cancer cells using fura-2 as an indicator. Tamoxifen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1013807731642

    authors: Chang HT,Huang JK,Wang JL,Cheng JS,Lee KC,Lo YK,Liu CP,Chou KJ,Chen WC,Su W,Law YP,Jan CR

    更新日期:2002-01-01 00:00:00

  • Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease.

    abstract::The response to primary chemotherapy is an important prognostic factor in patients with non metastatic breast cancer. In this study we compared the assessment of response performed by clinical palpation to that performed by echography and mammography in 141 out of 157 consecutive breast cancer patients (T2-4, N0-1, M0...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1012277325168

    authors: Fiorentino C,Berruti A,Bottini A,Bodini M,Brizzi MP,Brunelli A,Marini U,Allevi G,Aguggini S,Tira A,Alquati P,Olivetti L,Dogliotti L

    更新日期:2001-09-01 00:00:00

  • Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis.

    abstract::Cytochrome P450s are enzymes which catalyze Phase-I metabolism reactions; cytochrome P450 1A1 (CYP1A1) is a member of the CYP1 family and participates in the metabolism of a vast number of xenobiotics, as well as endogenous substrates. Four single nucleotide polymorphisms in CYP1A1 have been studied concerning their p...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-009-0694-5

    authors: Sergentanis TN,Economopoulos KP

    更新日期:2010-07-01 00:00:00

  • High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome.

    abstract:BACKGROUND:High insulin levels have been associated with poor outcomes in breast cancer. Our goal was to investigate whether hyperinsulinemia was associated with insulin resistance in a cohort of newly diagnosed locoregional breast cancer patients and to examine associations of hyperinsulinemia with the broader insulin...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0019-0

    authors: Goodwin PJ,Ennis M,Bahl M,Fantus IG,Pritchard KI,Trudeau ME,Koo J,Hood N

    更新日期:2009-04-01 00:00:00

  • Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial.

    abstract::We studied the cost of follow-up of 472 breast cancer patients without distant metastasis after primary treatment in four different schedules in a randomized trial. The mean follow-up was 4.2 years. The four schedules differed in frequency of follow-up visits (every third or sixth month) and in intensity of diagnostic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-005-5199-2

    authors: Kokko R,Hakama M,Holli K

    更新日期:2005-10-01 00:00:00

  • Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer.

    abstract::Epidermal growth factor receptor (EGFr) levels were analyzed in 140 primary breast cancer specimens by immunohistochemical assay (ICA), competitive binding assay (BA), or enzyme immunoassay (EIA). Thirty-nine of 118 specimens (33.1%) were scored as positive by ICA, 30 of 116 (25.9%; cut-off level 10 fmol/mg protein) b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00666582

    authors: Iwase H,Kobayashi S,Itoh Y,Kuzushima T,Yamashita H,Iwata H,Naito A,Yamashita T,Itoh K,Masaoka A

    更新日期:1993-12-01 00:00:00

  • Analysis of the breast cancer methylome using formalin-fixed paraffin-embedded tumour.

    abstract:PURPOSE:Aberrant DNA methylation occurs frequently in breast carcinogenesis. Tools for translational epigenetic studies of breast cancer involving formalin-fixed paraffin-embedded (FFPE) human tissues have now been developed. Few studies have measured genome-wide methylation in DNA derived from paraffin-embedded tumour...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3971-0

    authors: Wong EM,Joo JE,McLean CA,Baglietto L,English DR,Severi G,Wu HC,Terry MB,Hopper JL,Milne RL,Giles GG,Southey MC

    更新日期:2016-11-01 00:00:00

  • Microsatellite genotyping reveals a signature in breast cancer exomes.

    abstract::Genomic instability at microsatellite loci is a hallmark of many cancers, including breast cancer. However, much of the genomic variation and many of the hereditary components responsible for breast cancer remain undetected. We hypothesized that variation at microsatellites could provide additional genomic markers for...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2908-8

    authors: McIver LJ,Fonville NC,Karunasena E,Garner HR

    更新日期:2014-06-01 00:00:00

  • Hormone receptors and obesity in Japanese women with breast cancer.

    abstract::An association between hormone receptors in primary breast cancer and obesity determined prior to mastectomy was investigated in 128 Japanese women. The following criteria for obesity were used: (1) weight greater than or equal to 60 kg (132 lbs), (2) weight kg/height cm-105 greater than or equal to 1.3, (3) weight lb...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805867

    authors: Kuno K,Fukami A,Hori M,Kasumi F

    更新日期:1981-01-01 00:00:00

  • Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas.

    abstract:PURPOSE:The objective of this study is to understand an impact of financial burden on the adjuvant hormonal therapy (AHT) adherence and persistence for insured women aged 18-64 with early breast cancer in Texas. METHODS:We conducted a retrospective cohort study using claims data for population insured by Blue Cross Bl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4704-3

    authors: Kim J,Rajan SS,Du XL,Franzini L,Giordano SH,Morgan RO

    更新日期:2018-06-01 00:00:00

  • Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer.

    abstract::The aim of this study was to assess the intensity of diagnostic testing and cancer treatment of 335 women with advanced breast cancer during their last 6 months before death between 1995 and 1998 in the Pirkanmaa and Satakunta health care districts and to compare it to the practice in earlier decades, the 1970s and 19...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9224-x

    authors: Asola R,Huhtala H,Holli K

    更新日期:2006-11-01 00:00:00

  • Mutation analysis of PALB2 gene in French breast cancer families.

    abstract::Several population-based and family-based studies have demonstrated that germline mutations of the PALB2 gene (Partner and Localizer of BRCA2) are associated with an increased risk of breast cancer. Distinct mutation frequencies and spectrums have been described depending on the population studied. Here we describe th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3625-7

    authors: Damiola F,Schultz I,Barjhoux L,Sornin V,Dondon MG,Eon-Marchais S,Marcou M,GENESIS Study Investigators.,Caron O,Gauthier-Villars M,de Pauw A,Luporsi E,Berthet P,Delnatte C,Bonadona V,Maugard C,Pujol P,Lasset C,Longy M

    更新日期:2015-12-01 00:00:00

  • The effect of thrombospondin-1 on breast cancer metastasis.

    abstract::Thrombospondin-1 (TSP-1) has been proposed to have both pro-metastatic and anti-metastatic properties. To elucidate its role in breast cancer metastasis, we compared tumor progression in the polyomavirus middle T antigen (Pyt) transgenic mouse and the TSP-1-null Pyt transgenic mouse. We characterized the tumors in the...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-9992-6

    authors: Yee KO,Connolly CM,Duquette M,Kazerounian S,Washington R,Lawler J

    更新日期:2009-03-01 00:00:00

  • Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients.

    abstract:BACKGROUND:In several neoplastic diseases, immunosuppression has been shown to correlate with disease stage, progression, and outcome. As the prognosis for metastatic breast cancer is still pessimistic, additional strategies are being sought to improve survival. Local immunosuppression in sentinel node biopsies from 24...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1016009913699

    authors: Schüle J,Bergkvist L,Håkansson L,Gustafsson B,Håkansson A

    更新日期:2002-07-01 00:00:00

  • Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race.

    abstract:PURPOSE:To investigate whether treatment (surgery, radiation therapy, and endocrine therapy) contributes to racial disparities in outcomes of ductal carcinoma in situ (DCIS). PATIENTS AND METHODS:The analysis included 8184 non-Hispanic White and 954 non-Hispanic Black women diagnosed with DCIS between 1996 and 2011 an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-4030-6

    authors: Madubata CC,Liu Y,Goodman MS,Yun S,Yu J,Lian M,Colditz GA

    更新日期:2016-12-01 00:00:00

  • Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.

    abstract::This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer. This was a multicenter, open-label, randomized study. Primary endpoint was a non-in...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-010-1332-y

    authors: Masuda N,Iwata H,Rai Y,Anan K,Takeuchi T,Kohno N,Takei H,Yanagita Y,Noguchi S

    更新日期:2011-04-01 00:00:00

  • Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases.

    abstract::To evaluate the prognostic relevance of Ki-67 and topoisomerase IIalpha expression in relation to tumor stage, grade, and hormone receptor content, 942 ductal infiltrating carcinomas of the breast were examined by means of the monoclonal antibodies Ki-S11 (Ki-67) and Ki-S4 (topoisomerase IIalpha). pS2, c-erbB2, and p5...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006159016703

    authors: Rudolph P,MacGrogan G,Bonichon F,Frahm SO,de Mascarel I,Trojani M,Durand M,Avril A,Coindre JM,Parwaresch R

    更新日期:1999-05-01 00:00:00

  • High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation.

    abstract::The specific role of dietary fat in breast cancer progression is unclear, although a low-fat diet was associated with decreased recurrence of estrogen receptor alpha negative (ER(-)) breast cancer. ER(-) basal-like MDA-MB-231 and MDA-MB-436 breast cancer cell lines contained a greater number of cytoplasmic lipid dropl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0594-8

    authors: Antalis CJ,Arnold T,Rasool T,Lee B,Buhman KK,Siddiqui RA

    更新日期:2010-08-01 00:00:00

  • A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

    abstract::Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experimen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805721

    authors: Allegra JC,Woodcock TM,Richman SP,Bland KI,Wittliff JL

    更新日期:1982-01-01 00:00:00

  • Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.

    abstract:OBJECTIVES:To validate the newly proposed American Joint Committee on Cancer (AJCC) prognostic staging system for breast cancer. METHODS:Surveillance, epidemiology, and end results (SEER) database (2010-2014) was accessed. Cumulative incidence function was conducted (through assessment of sub-distribution hazard) acco...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4577-x

    authors: Abdel-Rahman O

    更新日期:2018-02-01 00:00:00

  • Association of body mass index, physical activity, and reproductive histories with breast cancer: a case-control study in Gifu, Japan.

    abstract::To further clarify risk factors for breast cancer in Japanese women, a self-administered questionnaire was completed by 157 cases with histologically confirmed breast cancer from 1989 to 1993 and by 369 age and residential area matched controls in Gifu, Japan. Conditional logistic regression model was used to assess t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005745824388

    authors: Hu YH,Nagata C,Shimizu H,Kaneda N,Kashiki Y

    更新日期:1997-03-01 00:00:00

  • Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin.

    abstract::Forty-one women with non-metastatic but locally advanced breast cancer were treated by modified radical or radical mastectomy, and were then randomized to receive one of two adjuvant chemotherapy regimens. Regimen A consisted of 6 months of cyclophosphamide, adriamycin, and fluorouracil (CAF) followed by 6 months of c...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01806692

    authors: Casper ES,Guidera CA,Bosl GJ,Hakes TB,Kaufman RJ,Shurgot B,Kinne DW

    更新日期:1987-01-01 00:00:00

  • ROCK: a breast cancer functional genomics resource.

    abstract::The clinical and pathological heterogeneity of breast cancer has instigated efforts to stratify breast cancer sub-types according to molecular profiles. These profiling efforts are now being augmented by large-scale functional screening of breast tumour cell lines, using approaches such as RNA interference. We have de...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0945-5

    authors: Sims D,Bursteinas B,Gao Q,Jain E,MacKay A,Mitsopoulos C,Zvelebil M

    更新日期:2010-11-01 00:00:00

  • Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.

    abstract::Prognosis of early beast cancer is heterogeneous. Today, no histoclinical or biological factor predictive for clinical outcome after adjuvant anthracycline-based chemotherapy (CT) has been validated and introduced in routine use. Using DNA microarrays, we searched for a gene expression signature associated with metast...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1003-z

    authors: Bertucci F,Borie N,Roche H,Bachelot T,Le Doussal JM,Macgrogan G,Debono S,Martinec A,Treilleux I,Finetti P,Esterni B,Extra JM,Geneve J,Hermitte F,Chabannon C,Jacquemier J,Martin AL,Longy M,Maraninchi D,Fert V,Birnb

    更新日期:2011-06-01 00:00:00

  • Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.

    abstract:PURPOSE:Immunotherapy has recently been shown to improve outcomes for advanced PD-L1-positive triple-negative breast cancer (TNBC) in the Impassion130 trial, leading to FDA approval of the first immune checkpoint inhibitor in combination with taxane chemotherapy. To further develop predictive biomarkers and improve the...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05936-4

    authors: Deng J,Thennavan A,Shah S,Bagdatlioglu E,Klar N,Heguy A,Marier C,Meyn P,Zhang Y,Labbe K,Almonte C,Krogsgaard M,Perou CM,Wong KK,Adams S

    更新日期:2021-01-01 00:00:00

  • Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population.

    abstract::Trinucleotide repeat-containing 9 (TNRC9), a high mobility group chromatin-associated protein, has been implicated in breast cancer metastasis to the bone. Recently, several single nucleotide polymorphisms (SNPs) of TNRC9 were identified as novel breast cancer susceptibility loci by whole genome association studies, e...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0809-z

    authors: Liang J,Chen P,Hu Z,Shen H,Wang F,Chen L,Li M,Tang J,Wang H,Shen H

    更新日期:2010-11-01 00:00:00

  • Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast.

    abstract::Following mastectomy, patients with operable breast cancer underwent postoperative irradiation of the chest wall and regional lymph nodes. They were then assigned at random to receive no further therapy, ovarian irradiation (2000 rad in five days) or ovarian irradiation in the same dosage plus prednisone, 7.5 mg daily...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01855127

    authors: Meakin JW,Allt WE,Beale FA,Bush RS,Clark RM,Fitzpatrick PJ,Hawkins NV,Jenkin RD,Pringle JF,Reid JG

    更新日期:1983-01-01 00:00:00

  • Receipt of locoregional therapy among young women with breast cancer.

    abstract::Although younger women with breast cancer have the most to gain from receipt of optimal care, few data are available regarding their receipt of locoregional breast cancer treatments. We identified 317,596 women aged 18-64 who were diagnosed with invasive breast cancer at hospitals reporting to the National Cancer Data...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2156-8

    authors: Freedman RA,Virgo KS,Labadie J,He Y,Partridge AH,Keating NL

    更新日期:2012-10-01 00:00:00

  • Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II.

    abstract::Findings from epidemiologic studies of oxidative stress biomarkers and breast cancer have been mixed, although no studies have focused on estrogen receptor-negative (ER-) tumors which may be more strongly associated with oxidative stress. We examined prediagnostic plasma fluorescent oxidation products (FlOP), a global...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3861-5

    authors: Hirko KA,Fortner RT,Hankinson SE,Wu T,Eliassen AH

    更新日期:2016-07-01 00:00:00

  • Macromolecular interstitial clearance, tumour vascularity, other prognostic factors and breast cancer survival.

    abstract:BACKGROUND:Clearance of large molecules from the interstitial space is an important function of lymphatics and is affected by local pathologic changes. OBJECTIVE:To determine if the clearance rate of interstitially injected albumin is correlated to tumour characteristics and outcome in women with invasive breast cance...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005749825449

    authors: Sterns EE,SenGupta S,Zee B

    更新日期:1997-01-01 00:00:00